Navigation Links
CuraGen to Present CR011-vcMMAE Data at ASCO
Date:5/28/2009

- Update from Advanced Breast Cancer and Melanoma Studies

- Conference Call to be Hosted on Wednesday, June 3, 2009 at 11:00 am

BRANFORD, Conn., May 28 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN) today announced plans for three data presentations from its ongoing clinical trials of CR011-vcMMAE, an antibody-drug conjugate that targets GPNMB, in patients with advanced breast cancer and melanoma at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida.

The titles, dates, and times of the presentations are as follows:

#9032 A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate targeting glycoprotein NMB in patients with advanced melanoma. Sunday, May 31, 2009, poster presentation from 8:00 AM - 12:00 PM with a discussion session from 11:30 AM - 12:30 PM.

#9063 Pharmacokinetics of CR011-vcMMAE, an antibody-drug conjugate, in a phase I study of patients with advanced melanoma. Monday, June 1, 2009, poster presentation from 8:00 AM - 12:00 PM.

#1067 A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate, in patients with locally advanced or metastatic breast cancer. Monday, June 1, 2009, poster presentation from 1:00 PM - 5:00 PM.

Abstracts are available and can be viewed on the ASCO Web site at www.asco.org.

Reprints of the presentations will be made available on CuraGen's website at http://www.curagen.com or can be requested by emailing info@cu
'/>"/>

SOURCE CuraGen Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
10. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
11. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...25 Cempra Pharmaceuticals Inc. tod... and chief executive officer, will present at the ...t 8:50 a.m. EST, December 1, 2009, at The New York...l provide an overview of the company,s two leading... drug-resistant pathogens including MRSA. ,, A...
(Date:11/25/2009)...5 ChemoCentryx, Inc., announced ...pany,s PROTECT-1 (the Prospective Randomized Oral ...aficet-EN(TM) (CCX282-B) in patients with moderate...fficacy with a favorable safety and tolerability p...al efficacy in the reduction of disease severity a...
(Date:11/24/2009)...Newswire-FirstCall/ -- Vermillion, Inc. (VRML) (Pi...Plan of Reorganization and Disclosure Statement to...kruptcy Court for the District of Delaware. A hear...nt is presently scheduled for December 8, 2009, wi...eduled for January 7, 2010. ,, The Plan calls ...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 6Vermillion Files Plan of Reorganization 2Vermillion Files Plan of Reorganization 3Vermillion Files Plan of Reorganization 4Cell Biosciences Signs Agreement to Acquire Alpha Innotech 13890 1Cell Biosciences Signs Agreement to Acquire Alpha Innotech 13890 2Cell Biosciences Signs Agreement to Acquire Alpha Innotech 13890 3Cell Biosciences Signs Agreement to Acquire Alpha Innotech 13890 4Cell Biosciences Signs Agreement to Acquire Alpha Innotech 13890 5Colon Cancer Screenings Still Too Low 3A Study 56371 1Colon Cancer Screenings Still Too Low 3A Study 56371 2Colon Cancer Screenings Still Too Low 3A Study 56371 3The Beryl Institute Sponsors Free Customer Service Webinar with Robert Reiss 56368 1The Beryl Institute Sponsors Free Customer Service Webinar with Robert Reiss 56368 2
... 10 non-diabetic patients treated with,Exforge ach...ional average decrease of 20 mmHg in,systolic bloo...r,reductions seen with previous monotherapy[1] , ...t treatment target levels[2] and most require two ...ASEL, Switzerland, May 21, 2007 - Exforge®,a ...
... recently approved by FDA for long-term maintenanc...nstrate first,nebulized formoterol fumarate provid... formoterol, enhanced patient quality of,life, and... 2007 /PRNewswire/ -- Data presented at the,Intern...y (ATS),demonstrate that Perforomist (formoterol f...
Other Medicine Technology:Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 2Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 3Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 4Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 5Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 6Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 7Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 8Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 2Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 3Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 4Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 5Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 6Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 7
(Date:11/27/2009)...s Ltd. today issued its latest biochemical analysi...he lethality of the virus has dropped from its pea...break in the spring of 2009 to resting non-epidemi...ectivity count, however, remains increased. , ...009 -- Biotech firm Replikins Ltd., which has anal...
(Date:11/27/2009)...7 Team Garmin-Slipstream, the elit...ethical sporting and developing the next generatio...ll become Team Garmin-Transitions with the additio...eam. Transitions Optical is the world,s leading ma...advanced photochromic technology in the widest sel...
(Date:11/27/2009)...conomic burdens, study predicts , , FRID...le with diabetes in the United States is expected ...icts. , That would bring the total by 2034 to a... 23.7 million today. , , At the same time, the c...the study also warns, rising from an estimated $11...
(Date:11/27/2009)...ers who use medical load cells at the heart of the...ging in technology partner Flintec early in the de...ical manufacturers are calling in Flintec load cel...ensuring that progress will not be constrained by ...technology. , (PRWEB) Nov...
(Date:11/26/2009)... living with diabetes will nearly double, increasi...34. Over the same period, spending on diabetes wil...billion, even with no increase in the prevalence o...Chicago report in the December issue of Diabetes ...ed by Medicare will rise from 8.2 million to 14.6 ...
Breaking Medicine News(10 mins):Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3
...olled when weary, MRI study shows , MONDAY, Oct. 2...r a bad night,s sleep? Scientists may now know wh... the brain,s emotional centers to dramatically ove...heightened emotional response in sleep-deprived pe...
...nology innovation for healthcare., CHICAGO and RE...ers Group (MS-HUG) and Microsoft Corp. today,annou...care Innovation,Awards. The contest, open to any h...com/cgi-bin/prnh/20000822/MSFTLOGO ) Now in its 1...
...ON, the healthcare,industry,s flagship solution fo..., makes it easier for users to gather and process ...ase of VISION 4.0 today. Vendormate,VISION 4.0 is ...e competition by,asking the customer how to improv...
...ntries are vitally important in the fight against ... conduct their work, according to a new commentary... , Researchers from Imperial College London, wh...ology and expertise with those in the developing w...
...hat causes epileptic seizures, but researchers fro...closer to solving this puzzle with the help of the...mouse. , This is the first human genetic mutation... genesis of epilepsy, which will aid in the develo...
...ors finds too few health tests , MONDAY, Oct. 22 (... vulnerable elderly Medicare, Medicaid patients is...ort. , Researchers at the University of California...eived by more than 100,000 community-dwelling peop...
Other Medicine News:Health News:Sleepless Nights Make for Grumpier Brains 2Health News:Call for Entries Announced for 2008 MS-HUG Innovation Awards 2Health News:Call for Entries Announced for 2008 MS-HUG Innovation Awards 3Health News:Vendormate VISION 4.0(TM) Streamlines Healthcare Security and Compliance Efforts 2Health News:Fight against HIV needs local scientists, say researchers 2Health News:Childhood epilepsy research offers new hope for seizure control 2Health News:Most Elderly Don't Get Good Medical Care: Study 2
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
Medicine Products: